Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Call Transcript
Operator: Good afternoon. Welcome to Sage Therapeutics’ Third Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Sage Therapeutics Inc. (SAGE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 1,499,065 | $10,823,249 | +542% | 0% |
| 2. | Palo Alto Investors William Leland Edwards | 1,010,833 | $7,298,214 | 0.94% | |
| 3. | D E Shaw D. E. Shaw | 647,032 | $4,671,571 | +100% | 0% |
| 4. | Leucadia National Ian Cumming And Joseph Steinberg | 622,473 | $4,494,255 | +114% | 0.03% |
| 5. | Citadel Investment Group Ken Griffin | 609,502 | $4,400,604 | +31% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.64 | 2,000 | 3,000 | 2023-08-09 | Filing | ||
| $50.50 | 1,000 | 1,000 | 2023-05-09 | Filing | ||
| $34.48 | 14,500 | 46,940 | 2022-11-10 | Filing | ||
| $31.45 | 8,000 | 8,000 | 2022-05-05 | Filing | ||
| $43.15 | 23,640 | 32,440 | 2021-08-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.90 | 3,838 | 121,981 | 2023-02-10 | Filing | ||
| $44.47 | 7,805 | 125,819 | 2023-02-10 | Filing | ||
| $160.58 | 8,000 | 2,535 | 2019-08-15 | Filing | ||
| $171.39 | 475 | 12,115 | 2019-05-29 | Filing | ||
| $170.40 | 400 | 12,590 | 2019-05-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,061,996 | $131,363,453 | 0.02% | |
| 2. | 5,482,477 | $118,805,276 | 0% | |
| 3. | 5,319,360 | $115,270,531 | 0% | |
| 4. | 5,197,019 | $112,619,402 | 1.75% | |
| 5. | 4,663,900 | $101,066,713 | 0% |
News See All
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. Welcome to Sage Therapeutics Second Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Sage Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.8 EPS, expectations were $-1.63. Sage Therapeutics, Inc.
5 Best All-Time Stocks To Invest In
In this piece, we will take a look at the five best all time low stocks to invest in.
12 Best Depressed Stocks To Buy in 2024
JPMorgan Chief Jamie Dimon, in his latest letter to shareholders, has warned that the real odds of soft landing a quite low when compared to market expectations.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript
Operator: Good morning. Welcome to SAGE Therapeutics' Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions].
5 Most Promising Psychedelic Stocks According to Hedge Funds
In this piece, we will take a look at the five most promising psychedelic stocks according to hedge funds.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript
Operator: Good morning. Welcome to Sage Therapeutics' Third Quarter 2023 Conference Call. [Operator Instructions].
Aristotle Atlantic’s Large Cap Growth Strategy Sold Sage Therapeutics (SAGE) on Uncertainty Surrounding the Company
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2023 investor letter. A copy of the same can be downloaded here.